==== Reference: Usmani SS, Bedi G, Samuel JS, Singh S, Kalra S, Kumar P, et al. (2017) THPdb: Database of FDA-approved peptide and protein therapeutics. PLoS ONE 12(7) e0181748.====

Detailed description page of THPdb

This page displays user query in tabular form.

1842 details
Primary information
ThPP IDTh1230
Therapeutic Peptide/Protein NameHuman Varicella-Zoster Immune Globulin
SequenceNA view full sequnce in fasta
Functional ClassificationIIIa
Molecular WeightNA
Chemical FormulaNA
Isoelectric PointNA
HydrophobicityNA
Melting Point (℃)NA
Half Life26.2 days
DescriptionHuman Varicella-Zoster Immune Globulin is a solvent/detergent-treated sterile liquid preparation of purified human immune globulin G (IgG) containing antibodies to varicella zoster virus (anti-VZV).
Indication/DiseaseIndicated for reducing the severity of chicken pox (varicella zoster virus) infections in high risk individuals after exposure
PharmacodynamicsProvides passive immunization for nonimmune individuals exposed to varicella zoster virus, thereby reducing the severity of varicella infections
Mechanism of ActionNA
ToxicityNA
MetabolismNA
AbsorptionPeak plasma time: 4.5 days, Peak plasma concentration: 136 mIU/mL
Volume of DistributionNA
Clearance0.204 mL/day
CategoriesAntibody
Patents NumberNA
Date of IssueNA
Date of ExpiryNA
Drug InteractionThe passive transfer of antibodies with immune globulin administration may impair the efficacy of live attenuated virus vaccines such as measles, rubella, mumps and varicella
Targetvaricella zoster virus
Information of corresponding available drug in the market
Brand NameVARIZIG
CompanyNA
Brand DiscriptionVARIZIG [Varicella Zoster Immune Globulin (Human)] is a solvent/detergent-treated sterile liquid preparation of purified human immune globulin G (IgG) containing antibodies to varicella zoster virus (anti-VZV). VZV is the causative agent of chickenpox. VARIZIG is prepared from plasma donated by healthy, screened donors with high titers of antibodies to VZV, which is purified by an anion-exchange column chromatography manufacturing method
Prescribed forIt is indicated for post-exposure prophylaxis of varicella in high risk individuals.
Chemical NameNA
FormulationIt is available in a single-use vial of 125 IU. Each 125 IU vial of VARIZIG contains less than 156 milligrams of total protein, mostly human immune globulin G (IgG). VARIZIG contains no preservative
Physcial Appearncelyophilized powder for solution
Route of AdministrationIntramuscular
Recommended DosageDepending on patient size, divide the IM dose and administer in 2 or more injection sites; not to exceed 3 mL/injection site
ContraindicationHypersensitivity to human immunoglobulins
Side EffectsThe most common adverse drug reactions (reported by ≥ 1% of subjects) observed in clinical trials for all subjects and patients (n=601) are the following:injection site pain (3%),headache (2%),rash (including terms pruritus, rash, rash erythematous, rash vesicular and urticaria) (1%),fatigue (1%),chills (1%),nausea (1%)
Useful Linkhttp://www.rxlist.com/varizig-drug.htm , http://reference.medscape.com/drug/varizig-varicella-zoster-immune-globulin-human-343145#0
PubMed ID6341478
3-D StructureN.A.